Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980–2016)

References

• Liu JKH. The history of monoclonal antibody development: Progress, remaining challenges and future innovations. Ann Med Surg 2014; 3(4):113-6; https://doi.org/10.1016/j.amsu.2014.09.001
   PubMedGoogle Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015; 15:361-70; PMID:25998715; https://doi.org/10.1038/nrc3930
   PubMed Web of Science ®Google Scholar
• Firestone Inventing. The Global Map of Monoclonal Antibody Drugs 2016 Report. Hangzhou, China: Firestone; 2016. Available at: http://www.hsmap.com/precision_medical_detail.html?pm_child=%E6%8A%97%E4%BD%93%E8%8D%AF%E7%89%A9&report_id=115&report_name=%E7%81%AB%E7%9F%B3%E5%8F%91%E5%B8%83-%E6%8A%97%E4%BD%93%E8%8D%AF%E7%89%A9%E5%85%A8%E7%90%83%E5%9C%B0%E5%9B%BE
   Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015; 7(1):9-14; PMID:25529996; https://doi.org/10.4161/19420862.2015.989042
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; https://doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Schiff R, Osborne Ck. Targeting HER2 for the treatment of breast cancer. Annu Rev Med 2015; 66:111-28; PMID:25587647; https://doi.org/10.1146/annurev-med-042513-015127
   PubMed Web of Science ®Google Scholar
• Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014; 12:132; PMID:25285786; https://doi.org/10.1186/s12916-014-0132-3
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001; 2:127-37; https://doi.org/10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Li HC, Wang M, Xu PY. Analysis of monoclonal antibody research literatures in the world. J Prev Med Inf 2010; 26(4):298-304
   Google Scholar
• Ma LF, Chen LB, Zhang HL, Tian L. Monoclonal antibody analysis based on bibliometrics. J Med Informatics 2010; 31(11):41-45. Chinese
   Google Scholar
• Gao YH, Xu SJ, Diao TX. Advances in research of antibody drugs. Chinese J New Drugs 2014; 23(20):2414-7. Chinese
   Google Scholar
• Hood W, Wilson C. The literature of bibliometrics, scientometrics, and informetrics. Scientometrics 2001; 52(2):291-314; https://doi.org/10.1023/A:1017919924342
   Web of Science ®Google Scholar
• Small H. The relationship of information science to the social sciences: a co-citation analysis. Inf Process Manag 1981; 17(1):39-50; https://doi.org/10.1016/0306-4573(81)90040-6
   Web of Science ®Google Scholar
• Chen CM. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 2006; 57(3):359-77; https://doi.org/10.1002/asi.20317
   Web of Science ®Google Scholar
• Chen CM, Hu ZG, Liu SB, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther 2012; 12(5):593-608; PMID:22443895; https://doi.org/10.1517/14712598.2012.674507
   PubMed Web of Science ®Google Scholar
• Chen CM, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000-2014). Expert Opin Biol Ther 2014; 14(9):1295-17; PMID:25077605; https://doi.org/10.1517/14712598.2014.920813
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, McLendon RE, Bullard DE, Fredman P, Svennerholm L, Bigner DD. Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. Cancer Res 1986; 46(11):5933-40; PMID:3756930
   PubMed Web of Science ®Google Scholar
• Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008; 13:1619-33; PMID:17981654
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; https://doi.org/10.1093/intimm/13.12.1551
   PubMed Web of Science ®Google Scholar
• Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54:11-29; PMID:15780905; https://doi.org/10.1016/j.critrevonc.2004.10.011
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640-56; PMID:16904789; https://doi.org/10.1016/j.addr.2006.01.026
   PubMed Web of Science ®Google Scholar
• Morrision SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851-5; PMID:6436822; https://doi.org/10.1073/pnas.81.21.6851
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5; PMID:3713831; https://doi.org/10.1038/321522a0
   PubMed Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4; PMID:2247164; https://doi.org/10.1038/348552a0
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12:433-55; PMID:8011287; https://doi.org/10.1146/annurev.iy.12.040194.002245
   PubMed Web of Science ®Google Scholar
• Jostock T, Vanhove M, Brepoels E, Gool RV, Daukandt M, Wehnert A, Hegelsom RV, Dransfield D, Sexton D, Devlin M, et al. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 2004; 289:65-80; PMID:15251413; https://doi.org/10.1016/j.jim.2004.03.014
   PubMed Web of Science ®Google Scholar
• Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, Mccabe JG, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368:856-9; PMID:8159246; https://doi.org/10.1038/368856a0
   PubMed Web of Science ®Google Scholar
• Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7:13-21; PMID:8075633; https://doi.org/10.1038/ng0594-13
   PubMed Web of Science ®Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010; 1:314-22; PMID:21487506; https://doi.org/10.4161/self.1.4.13904
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiler S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao WH, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-9; PMID:12047962; https://doi.org/10.1016/S0140-6736(02)08512-4
   PubMed Web of Science ®Google Scholar
• Kindler V, Sappino A, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40; PMID:2647299; https://doi.org/10.1016/0092-8674(89)90676-4
   PubMed Web of Science ®Google Scholar
• Beese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, Macdonald TT. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455-66; PMID:8194690; https://doi.org/10.1016/0016-5085(94)90398-0
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A. Tumor necrosis factor α and interleukin 1ß in relapse of Crohn's disease. Lancet 1999; 353:459-61; PMID:9989717; https://doi.org/10.1016/S0140-6736(98)03339-X
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-53; PMID:8232330; https://doi.org/10.1016/0161-5890(93)90106-L
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Maclntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 2006; 130:323-33; PMID:16472588; https://doi.org/10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; https://doi.org/10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; https://doi.org/10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti–epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70(2):588-97; PMID:20068188; https://doi.org/10.1158/0008-5472.CAN-09-1417
   PubMed Web of Science ®Google Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. mAbs 2010; 2(2):129-36; PMID:20190561; https://doi.org/10.4161/mabs.2.2.11221
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121:5154-7; PMID:23678006; https://doi.org/10.1182/blood-2013-02-485623
   PubMed Web of Science ®Google Scholar
• Webb S. Pharma interest surges in antibody drug conjugate. Nat Biotechnol 2011; 29:297-8; PMID:21478833; https://doi.org/10.1038/nbt0411-297
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; https://doi.org/10.1038/256495a0
   PubMed Web of Science ®Google Scholar
• Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772; https://doi.org/10.1038/305537a0
   PubMed Web of Science ®Google Scholar
• Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: a bibliographic review. Toxicology 1995; 105(1):23-9; PMID:8638282; https://doi.org/10.1016/0300-483X(95)03123-W
   PubMed Web of Science ®Google Scholar
• Buss N APS, Henderson SJ, McFarlane M, Shenton JM, Haan LD. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012; 12:615-22; PMID:22920732; https://doi.org/10.1016/j.coph.2012.08.001
   PubMed Web of Science ®Google Scholar
• Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40:717-21; PMID:7471090
   PubMed Web of Science ®Google Scholar
• Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772; https://doi.org/10.1038/305537a0
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314:628-31; PMID:2859527; https://doi.org/10.1038/314628a0
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987; 17(1):105-11; PMID:3102250; https://doi.org/10.1002/eji.1830170118
   PubMed Web of Science ®Google Scholar
• Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985; 229(4708):81-3; PMID:3925553; https://doi.org/10.1126/science.3925553
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5; PMID:5432063; https://doi.org/10.1038/227680a0
   PubMed Web of Science ®Google Scholar
• LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86:4220-4; PMID:2726771; https://doi.org/10.1073/pnas.86.11.4220
   PubMed Web of Science ®Google Scholar
• Nitta T, Yagita H, Okumura K, Sato K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335(8686):368-71; https://doi.org/10.1016/0140-6736(90)90205-J
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher Jr CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324(7):429-36; PMID:1988827; https://doi.org/10.1056/NEJM199102143240701
   PubMed Web of Science ®Google Scholar
• Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science 1988; 242(4877):423-6; PMID:3140379; https://doi.org/10.1126/science.3140379
   PubMed Web of Science ®Google Scholar
• Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992; 7:78-81
   Google Scholar
• Riethmuller G, Gruber R, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343(8907):1177-83; PMID:7909866; https://doi.org/10.1016/S0140-6736(94)92398-1
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12:433-55; PMID:8011287; https://doi.org/10.1146/annurev.iy.12.040194.002245
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease. N Engl J Med 1997; 337:1029-36; PMID:9321530; https://doi.org/10.1056/NEJM199710093371502
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Tagan S, Hanauer SB, Mayer L, Hogezand RAV, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-405; PMID:10228190; https://doi.org/10.1056/NEJM199905063401804
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8):2825-33; PMID:9704735
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Hogezand RAV, Braakman T, DeWoody KL, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117(4):761-9; PMID:10500056; https://doi.org/10.1016/S0016-5085(99)70332-X
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; https://doi.org/10.1038/74704
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Assche GV, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-8; PMID:12584368; https://doi.org/10.1056/NEJMoa020888
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; https://doi.org/10.1038/nbt1142
   PubMed Web of Science ®Google Scholar
• Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of Intact Bispecific Antibody Results in efficient tumor cell killing. J Immunol 1999; 163(3):1246-52; PMID:10415020
   PubMed Web of Science ®Google Scholar
• Phillips GDL, Li GM, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RVJ, Lutz RJ, et al. Targeting HER2-positive breast cancer with Trastuzumab-DM1, an Antibody–Cytotoxic drug conjugate. Cancer Res 2008; 68(22):9280-90; PMID:19010901; https://doi.org/10.1158/0008-5472.CAN-08-1776
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363:1812-21; PMID:21047225; https://doi.org/10.1056/NEJMoa1002965
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing P, Bovee TD, Siegall CB, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778-84; PMID:12778055; https://doi.org/10.1038/nbt832
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26(8):925-36; PMID:18641636; https://doi.org/10.1038/nbt.1480
   PubMed Web of Science ®Google Scholar
• Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, et al. Location Matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20(2):161-7; PMID:23438745; https://doi.org/10.1016/j.chembiol.2013.01.010
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851-5; PMID:6436822; https://doi.org/10.1073/pnas.81.21.6851
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5; PMID:3713831; https://doi.org/10.1038/321522a0
   PubMed Web of Science ®Google Scholar
• Chen CM, Chen Y, Horowitz M, Hou HY, Liu ZY, Pellegrino D. Towards an explanatory and computational theory of scientific discovery. J Informetr 2009; 3:191-209; https://doi.org/10.1016/j.joi.2009.03.004
   Web of Science ®Google Scholar
• Chen CM, Song IY, Yuan XJ, Zhang J. The thematic and citation landscape of data and knowledge engineering (1985-2007). Data Knowl Eng 2008; 67:234-59; https://doi.org/10.1016/j.datak.2008.05.004
   Web of Science ®Google Scholar
• Chen CM, Dubin R, Kim MC. Orphan drugs and rare diseases: a scientometric review (2000-2014). Expert Opin Orphan Drugs 2014; 2(7):709-24; https://doi.org/10.1517/21678707.2014.920251
   Web of Science ®Google Scholar
• Person O. The intellectual base and research fronts of JASIS 1986-1990. JASIS 1994; 45(1):31-8; https://doi.org/10.1002/(SICI)1097-4571(199401)45:1<31::AID-ASI4>3.0.CO;2-G
   Web of Science ®Google Scholar